KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 7028 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Optimizing the use of vilobelimab for the treatment of COVID-19. PMID 37421632 · Expert Opin Biol Ther · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result. PMID 37404828 · Front Immunol · 2023 The study is a Phase I/II randomized trial of a cancer vaccine for COVID-19 prevention. It meets criteria for oncology, human, randomized, and drug intervention. However, it is not a Phase III/IIIb or definitive Phase II/III trial, and it does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. The primary outcomes are safety and incidence of moderate-severe COVID-19, which are not time-to-event endpoints. Therefore, it is ineligible.
H L
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial]. PMID 37315247 · Zh Nevrol Psikhiatr Im S S Korsakova · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden. PMID 37304255 · Front Immunol · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. PMID 37257422 · Ophthalmic Res · 2023 The study is a randomized, Phase 3b oncology trial with a drug intervention, but the pre-specified primary endpoint is a safety/management endpoint (ocular side effects), not a time-to-event efficacy endpoint (like OS, PFS, etc.). While the study was stopped due to interim survival data from a separate trial, the abstract does not report Kaplan-Meier curves, hazard ratios, or formal time-to-event efficacy results for this study's own cohort. Therefore, it does not meet the inclusion criteria for a key secondary time-to-event efficacy endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial. PMID 37256558 · Expert Rev Pharmacoecon Outcomes Res · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prolonged continuous wound infusion of local anesthetic and steroid after major abdominal surgery to reduce opioid consumption: a randomized, double-blind trial. PMID 37194239 · Minerva Anestesiol · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine. PMID 37181705 · Front Public Health · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase II/III Study of Aceneuramic Acid Administration for GNE Myopathy in Japan. PMID 37125562 · J Neuromuscul Dis · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Generalized phase I-II designs to increase long term therapeutic success rate. PMID 37038957 · Pharm Stat · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H L B
旧查询独有 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study. PMID 37016933 · Technol Cancer Res Treat · 2023 The record is a randomized Phase III trial in human prostate cancer with primary results, but it is ineligible because it compares two radiotherapy techniques (prostate-only vs. whole pelvic radiotherapy) and does not include a drug intervention. Furthermore, the primary outcomes are dosimetric and hematologic, with no reported time-to-event efficacy endpoint (e.g., OS, PFS) or survival analysis (Kaplan-Meier, HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial. PMID 36928877 · PLoS One · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial. PMID 36926379 · Pain Res Manag · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia. PMID 36888640 · PLoS One · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety of levofloxacin as an antibiotic prophylaxis in the induction phase of children newly diagnosed with acute lymphoblastic leukemia: an interim analysis of a randomized, open-label trial in Brazil. PMID 36750202 · Braz J Infect Dis · 2023 While the record describes a randomized, phase III, drug-intervention oncology trial with original results, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The endpoints are safety and incidence-based (CPE colonization, C. difficile diarrhea, adverse events, febrile neutropenia).
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Vestibulotoxicity in Patients Undergoing Cisplatin-Based Cancer Treatment: A Phase IIIB Randomized Controlled Clinical Trial. PMID 36731442 · Audiol Neurootol · 2023 The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original report. However, the primary endpoint is the incidence of a toxicity (vestibulotoxicity), not a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is excluded per protocol.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endothelial dysfunction in ME/CFS patients. PMID 36730360 · PLoS One · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). PMID 36693773 · Semin Oncol · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. PMID 36641605 · J Prev Alzheimers Dis · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States. PMID 36601798 · J Med Econ · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies. PMID 36378864 · J Ocul Pharmacol Ther · 2023 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk. PMID 35165682 · Clin Infect Dis · 2022-Sep-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies. PMID 35148378 · Clin Infect Dis · 2022-Sep-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. PMID 36166026 · JAMA · 2022-Sep-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. PMID 36129998 · N Engl J Med · 2022-Sep-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants. PMID 36064672 · Vaccine · 2022-Sep-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vaccine efficacy trials for Crimean-Congo haemorrhagic fever: Insights from modelling different epidemiological settings. PMID 36058795 · Vaccine · 2022-Sep-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial. PMID 35960897 · J Clin Oncol · 2022-Sep-20 This is an updated report of a Phase III randomized trial in human oncology (cervical and endometrial cancer) with time-to-event efficacy endpoints (OS, DFS). However, the intervention compares intensity-modulated radiation therapy (IMRT) to conventional pelvic radiation therapy (CRT); both are radiation modalities, not a systemic drug intervention. The trial is non-drug-only, which excludes it per the adjudication rules.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. PMID 35943252 · Antimicrob Agents Chemother · 2022-Sep-20 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. PMID 35580297 · J Clin Oncol · 2022-Sep-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 5 Panel · risk visible
A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610. PMID 35472141 · Jpn J Clin Oncol · 2022-Sep-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. PMID 36116481 · Lancet · 2022-Sep-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. PMID 36116480 · Lancet · 2022-Sep-17 The study is a randomized, placebo-controlled Phase 3 trial of a drug (linzagolix) for symptomatic uterine fibroids, which is a non-malignant condition. The primary endpoint is a binary response rate (reduction in heavy menstrual bleeding), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an analysis using Kaplan-Meier or reporting a hazard ratio. Therefore, it does not meet the oncology or time-to-event criteria for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer - results of a randomized phase III trial (RAREST-02). PMID 36115962 · BMC Cancer · 2022-Sep-17 The study is a randomized Phase III trial in oncology with human subjects and reports primary results. However, it is excluded because the intervention (mobile app) is not a drug-containing intervention, and the primary and secondary endpoints are acute toxicity rates (toxicity grade proportions), not time-to-event efficacy endpoints such as OS, PFS, DFS, or TTP, which are required for this adjudication.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial. PMID 36546064 · Sci Bull (Beijing) · 2022-Sep-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Polypill Strategy in Secondary Cardiovascular Prevention. PMID 36018037 · N Engl J Med · 2022-Sep-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Association of hyperglycemia and computed tomographic perfusion deficits in patients who underwent endovascular treatment for acute ischemic stroke caused by a proximal intracranial occlusion: A subgroup analysis of a randomized phase 3 trial (MR CLEAN). PMID 35834861 · J Neurol Sci · 2022-Sep-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. PMID 35728048 · Blood Adv · 2022-Sep-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. PMID 36088292 · BMC Cancer · 2022-Sep-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. PMID 35442766 · J Clin Oncol · 2022-Sep-10 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference confirmed 2 Figure · 6 Panel · risk visible
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. PMID 34918028 · Clin Infect Dis · 2022-Sep-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. PMID 34864943 · Clin Infect Dis · 2022-Sep-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). PMID 36215226 · BMJ · 2022-Sep-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. PMID 36071409 · BMC Cancer · 2022-Sep-07 The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original results. However, it is excluded because the primary and secondary efficacy endpoints are not time-to-event outcomes (e.g., OS, PFS, DFS). The primary endpoint is pathologic complete response (bpCR), a categorical endpoint. No time-to-event endpoint or associated analysis (Kaplan-Meier, HR) is reported or referenced in the abstract.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials. PMID 36064325 · BMC Gastroenterol · 2022-Sep-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial. PMID 36254732 · BJS Open · 2022-Sep-02 The trial is a Phase III randomized oncology study with human participants and time-to-event endpoints. However, the primary comparison is the timing of surgery (≤8 weeks vs. >8 weeks) following chemoradiotherapy. The intervention does not explicitly involve a drug-containing regimen versus a control; the drug component (chemoradiotherapy) is standard preoperative treatment for both arms, and the randomized factor is the timing of the subsequent surgical procedure, not the drug itself. Therefore, it does not meet the criterion for a drug-containing intervention.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical Evaluation of an HTK Solution for Liver Transplantation: A Phase 3 Randomized Pilot Clinical Trial Study. PMID 37543887 · Arch Iran Med · 2022-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. PMID 35857290 · JAMA Dermatol · 2022-Sep-01 The study is an oncology Phase 3 randomized trial with a drug-containing intervention (topical hypericin) and original results. However, the primary endpoint is a categorical response rate (index lesion response rate), not a time-to-event endpoint. The intervention is a topical photodynamic therapy, which may be considered a device or procedure rather than a systemic drug administration per the criteria. No time-to-event outcomes (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analyses are reported in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. PMID 35763704 · J Clin Oncol · 2022-Sep-01 The study is a Phase III randomized oncology trial with a drug intervention and reports original primary results. However, the primary efficacy endpoint is pathologic complete response (pCR), which is a binary, non-time-to-event outcome. The abstract does not report a time-to-event endpoint such as OS, PFS, DFS, or include Kaplan-Meier or hazard ratio data. Therefore, it does not meet the criterion for a time-to-event efficacy endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. PMID 35687757 · Blood · 2022-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -